[HT-03] Newly Emerging Concepts on PSP and CBD

[HT-03-4] JALPAC: Longitudinal cohort study for PSP and CBD in Japan

Takeshi Ikeuchi¹, JALPAC Consortium² (1.Brain Research Institute, Niigata University, Japan, 2.JALPAC Consortium)

Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are neuropathologically characterized by accumulation of phosphorylated 4-repeat tau in brain. Clinical diagnosis of PSP and CBD is challenging because correlation between clinical phenotypes and underlying neuropathological findings is often inconsistent. Recently, new criteria for PSP diagnosis have been proposed by the Movement Disorder Society-endorsed Study Group. In addition, genetic analysis and molecular imaging study now provide useful information to make accurate diagnosis of PSP and CBD. With disease-modifying therapies being developed, accurate diagnosis of patients in early-stage disease is becoming more urgent. In this symposium, we will discuss how we can make diagnosis of PSP and CBD efficiently on the basis of recent progress of clinical, genetic, neuropathological and neuroimaging analyses.

Dr. Ikeuchi was graduated from Niigata University School of Medicine in 1991. He started residency program at Department of Neurology, Niigata University in 1993. He obtained Ph.D degree in human genetic of neurological diseases in 2000 from Niigata University. After graduation, he worked on dementia research as a postdoctoral fellow at the University of Chicago. He returned to Niigata University and became assistant professor of Department of Neurology in 2004. He became associate professor in 2011, and professor in 2013 at Brain Research Institute, Niigata University. He is a board-certified Neurologist, dementia practitioner, and medical geneticist. His major interests are clinical and translational research of neurodegenerative disorders through genetic and biomarker studies.